Free
$0
per month
- Delay1 min
- Filters1
- Watchlist1
- Integrations1 Platform
Subscription plans
All plans are subscription purchases. Switch between monthly and yearly billing, with yearly priced at 80% of the monthly total.
BioPharmSignal pricing is built around real-time biotech calendar monitoring, saved filters, watchlists, and alert workflows. The plans are designed for different levels of catalyst coverage, from light monitoring to heavier event-driven tracking. Choose a plan based on how many tickers, keywords, and integrations you need to run continuously.
Yearly billing saves 20% versus monthly.
Free
per month
Pro
per month
Ultra
per month
By continuing, you agree to the Terms of Service and Privacy Policy. Payments processed securely via Stripe. Need help? Contact [email protected].
These limits shape how fast alerts arrive, how many stocks you can monitor, and how precisely you can narrow the feed to the catalysts that matter most.
Track real-time biotech headlines alongside your calendar alerts so the next catalyst stays in context.
Save ticker and keyword alerts to keep the names you follow in view as new updates land.
Follow upcoming FDA target dates and regulatory milestones in one place.
Send alerts into Slack, Discord, Feishu, or other webhook tools when you want delivery outside the app.
BioPharmSignal pricing is built around alert speed, saved filters, watchlist capacity, and integration limits across the Free, Pro, and Ultra plans.
Pro is meant for focused biotech monitoring with limited filters and watchlists, while Ultra removes most limits for heavier event-driven workflows that need broader coverage and more integrations.
Yes. BioPharmSignal supports both monthly and yearly billing, with yearly pricing set below the full monthly total.
If you only need light monitoring or want to get familiar with the product first, the Free plan is the simplest starting point. Pro is the better fit once you need real-time coverage plus saved filters and watchlists.
Ultra makes more sense when you need broader biotech coverage, more saved filters, more watchlist flexibility, and more integration capacity for a heavier research or trading workflow.
The core company coverage is broad across U.S.-listed biotech and pharma stocks, but the plans differ in delay, saved filters, watchlist size, and workflow flexibility rather than in basic universe access.